We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Allergan, Inamed Smooth Out Concerns Over Reloxin

Law360 (May 14, 2007, 12:00 AM EDT) -- Botox marketer Allergan Inc. and Inamed Corp. have agreed to divest the rights to rival wrinkle buster Reloxin to alleviate concerns over the potential anti-competitive effects of their billion-dollar merger.

Allergan will sell off the rights to make and distribute Reloxin to resolve U.S. Federal Trade Commission’s charges that its $3.2 billion acquisition of Inamed would break antitrust laws, the FTC said Monday.

The FTC alleged that Allergan’s takeover of Inamed, which owns the rights to Reloxin, would add a few worry lines to competition regulators...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.